newsfilter
← Latest News
PR Newswire·

Miravo Healthcare™ Announces Receipt of Health Canada Notice of Compliance for the Pediatric Use of Blexten®

- Blexten Label Expanded to Include Ages as Young as 4 Years Old -- Includes Approval of 2.5mg/mL Oral Solution and 10mg orodispersible (Quick Melt) Tablet Formats -- Commercial Availability of Pediatric Formats Anticipated During Q1 2022 - MISSISSAU